Dr Reddys Laboratories Ltd 07 May 2024 12:00 AM
Dr Reddy`s Laboratories consolidated net profit rises 36.42% in the March 2024 quarter,
Net profit of Dr Reddy`s Laboratories rose 36.42% to Rs 1309.80 crore in the quarter ended March 2024 as against Rs 960.10 crore during the previous quarter ended March 2023. Sales rose 12.49% to Rs 7083.00 crore in the quarter ended March 2024 as against Rs 6296.80 crore during the previous quarter ended March 2023.For the full year,net profit rose 23.75% to Rs 5577.90 crore in the year ended March 2024 as against Rs 4507.30 crore during the previous year ended March 2023. Sales rose 13.54% to Rs 27916.40 crore in the year ended March 2024 as against Rs 24587.90 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales7083.006296.80 12 27916.4024587.90 14 OPM %25.8524.36 -28.4225.82 - PBDT1972.901644.60 20 8671.007298.70 19 PBT1605.201329.10 21 7201.006048.50 19 NP1309.80960.10 36 5577.904507.30 24 Powered by Capital Market - Live News
Dr Reddys Laboratories Ltd 07 May 2024 12:00 AM
Dr Reddys Laboratories AGM scheduled,
Dr Reddys Laboratories announced that the 40th Annual General Meeting(AGM) of the company will be held on 29 July 2024.Powered by Capital Market - Live News
Dr Reddys Laboratories Ltd 07 May 2024 12:00 AM
Board of Dr Reddys Laboratories recommends final dividend,
Dr Reddys Laboratories announced that the Board of Directors of the Company at its meeting held on 7 May 2024, inter alia, have recommended the final dividend of Rs 40 per equity Share (i.e. 800%) , subject to the approval of the shareholders.Powered by Capital Market - Live News
Dr Reddys Laboratories Ltd 03 May 2024 12:00 AM
Dr Reddy`s launches Doxycycline Capsules in the US,
Dr. Reddy`s Laboratories announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic equivalent of ORACEA� (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy`s Doxycycline Capsules, 40 mg, are supplied in bottle counts of 30.Powered by Capital Market - Live News
Dr Reddys Laboratories Ltd 19 Apr 2024 12:00 AM
Dr. Reddy`s launches condition management programme DailyBloom¿ IBS,
Dr. Reddy`s Laboratories announced the roll-out of its condition management programme DailyBloom� IBS, India`s first integrated care plan for Irritable Bowel Syndrome (IBS). The programme is based on extensive research and is enabled by a mobile application developed in-house. DailyBloom� IBS focuses on a comprehensive care plan that includes diet management, psychological and physical wellness support for patients with IBS. Dr. Reddy`s has launched the programme on `World IBS Day`, a day that aims to increase awareness of the IBS condition, discuss misconceptions, challenges and even stigma attached to it.Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now